Morgan Stanley: It’s Too Early to Be Bullish on the Market Now
Jinse Finance reported, citing market news released by Bloomberg analyst Walter Bloomberg, that Michael Wilson of Morgan Stanley has warned that, given the ongoing trade tensions between China and the US, weak earnings forecasts, and credit pressures, it is still too early to be bullish on the market. He stated that if the tensions persist beyond November, the S&P 500 Index could fall by as much as 11%. Wilson hopes that before confidence is restored, trade tensions will ease more clearly, earnings per share trends will stabilize, and liquidity will become more abundant. However, he expects the market to recover within 6-12 months. John Stoltzfus of Oppenheimer Holdings is also optimistic about the market, noting that the earnings of S&P 500 constituents have risen by 16% so far, exceeding expectations.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Crypto prices
More
